72 related articles for article (PubMed ID: 2080684)
21. [Pulmonary manifestations of systemic scleroderma: pathophysiologic and clinical significance of the activation of lung fibroblasts].
Behr J; Adelmann-Grill BC; Hein R; Schwaiblmair M; Degenkolb B; Krombach F; Fruhmann G
Pneumologie; 1995 Apr; 49(4):266-72. PubMed ID: 7792285
[TBL] [Abstract][Full Text] [Related]
22. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
[TBL] [Abstract][Full Text] [Related]
23. [Procollagen-III-peptide in bronchoalveolar lavage fluid as an index of fibrosis in sarcoidosis and idiopathic lung fibrosis?].
Teschler H; Costabel U; Ziesche R; Freitag L; Matthys H; Konietzko N
Pneumologie; 1990 Feb; 44 Suppl 1():217-8. PubMed ID: 2367369
[TBL] [Abstract][Full Text] [Related]
24. Tryptophan metabolism in chronic inflammatory lung disease.
Meyer KC; Arend RA; Kalayoglu MV; Rosenthal NS; Byrne GI; Brown RR
J Lab Clin Med; 1995 Dec; 126(6):530-40. PubMed ID: 7490512
[TBL] [Abstract][Full Text] [Related]
25. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
[TBL] [Abstract][Full Text] [Related]
26. [Interstitial lung fibrosis in rheumatoid arthritis--comparison of lung function and bronchoalveolar lavage].
Petermann W; Hoppe-Seyler S; Entzian P; Barth J
Pneumologie; 1990 Feb; 44 Suppl 1():540-1. PubMed ID: 2367460
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
28. Bronchoalveolar lavage in other interstitial lung diseases.
Costabel U; Guzman J; Bonella F; Oshimo S
Semin Respir Crit Care Med; 2007 Oct; 28(5):514-24. PubMed ID: 17975779
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
30. [Respiratory disorders in Sjögren's syndrome: its comparison with scleroderma and normal state].
Constantopoulos SH; Moutsopoulos HM
Ter Arkh; 1988; 60(4):46-8. PubMed ID: 3394096
[TBL] [Abstract][Full Text] [Related]
31. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases.
Reichenberger F; Schauer J; Kellner K; Sack U; Stiehl P; Winkler J
Lung; 2001; 179(3):163-74. PubMed ID: 11891606
[TBL] [Abstract][Full Text] [Related]
32. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients.
Luzina IG; Atamas SP; Wise R; Wigley FM; Choi J; Xiao HQ; White B
Arthritis Rheum; 2003 Aug; 48(8):2262-74. PubMed ID: 12905481
[TBL] [Abstract][Full Text] [Related]
33. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
34. Effects of ozone on normal and potentially sensitive human subjects. Part I: Airway inflammation and responsiveness to ozone in normal and asthmatic subjects.
Balmes JR; Aris RM; Chen LL; Scannell C; Tager IB; Finkbeiner W; Christian D; Kelly T; Hearne PQ; Ferrando R; Welch B
Res Rep Health Eff Inst; 1997 Jun; (78):1-37; discussion 81-99. PubMed ID: 9387195
[TBL] [Abstract][Full Text] [Related]
35. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis.
Rossi GA; Bitterman PB; Rennard SI; Ferrans VJ; Crystal RG
Am Rev Respir Dis; 1985 Apr; 131(4):612-7. PubMed ID: 3994157
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis and staging of scleroderma.
Winkelmann RK
Acta Derm Venereol; 1976; 56(2):83-92. PubMed ID: 58529
[TBL] [Abstract][Full Text] [Related]
37. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease.
Moodley YP; Lalloo UG
Chest; 2001 May; 119(5):1449-54. PubMed ID: 11348952
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and management of pulmonary fibrosis in scleroderma.
White B
Curr Rheumatol Rep; 2002 Apr; 4(2):108-12. PubMed ID: 11890875
[TBL] [Abstract][Full Text] [Related]
39. [Lung manifestation of progressive systemic scleroderma. Computerized tomographic findings].
Holzmann H; Jacobi V; Werner RJ; Stahl E
Hautarzt; 1994 Jul; 45(7):471-5. PubMed ID: 7928342
[TBL] [Abstract][Full Text] [Related]
40. A successful therapy with plasma exchange for interstitial pneumonia of progressive systemic sclerosis.
Tamura K; Akiyama J; Oono K; Kadowaki S; Shimada T
Intern Med; 1992 May; 31(5):649-54. PubMed ID: 1504429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
